US 11,306,140 B2Granted

Therapeutics for ocular immunoinflammatory diseases

AssigneeThe Schepens Eye Research Institute, Inc.

InventorsReza Dana, Sunil Chauhan, Yihe Chen

Life of this patent

Estimating the term…

Abstract

Methods and compositions for reducing the activity or number of memory Th17 cells in ocular tissue, and for treatment and/or prevention of ocular immunoinflammatory diseases are described.

Claims9

Dependent claims

A method for treating a subject afflicted with Dry Eye Disease (DED), comprising locally administering to an eye of the subject a composition consisting of a neutralizing anti-IL-15R antibody or an antibody that binds to IL-15, or a neutralizing anti-IL-7R antibody or an antibody that binds to IL-7, and an ophthalmically acceptable vehicle.

Dependencies are inferred from the claim text.

Facts

Application: 16/068,300Filed 6 Jan 2017 · us provisional application
Priority: 7 Jan 2016
Published: US 2019/0008765 A110 Jan 2019
Granted: 19 Apr 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07K 16/244
Against cytokines, lymphokines or interferons: interleukins [IL]
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61L 27/54
Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface…:…
A61P 27/04
Ophthalmic agents: artificial tears; Irrigation solutions

Family

Application62/275,946Us provisional application · filed 7 Jan 2016
US 2019/0008765 A1Pre-grant publication · published 10 Jan 2019
US 11,306,140 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results